BALIMONT-related microbiome research
The indexed publication discusses strains including Lactobacillus reuteri ATCC 23272, Lacticaseibacillus rhamnosus DSM 20021 and Lactiplantibacillus plantarum DSM 20174.
Science & Publications
Science & Publications
Published evidence, clearly bounded
Scientific references are presented as research records, not as proof that every BALIMONT commercial proposal has the same composition, dose, quality profile or clinical effect.
Referenced publication
Evidence interpretation
- Probiotic evidence is strain-specific and cannot be transferred automatically between strains or formulations.
- A publication does not by itself establish commercial availability, product equivalence, regulatory authorisation or a permitted claim.
- Commercial dossiers should connect the exact ingredient identity, manufacturing specification, stability, intended dose and target market to the supporting evidence.
Background reference: Frontiers in Microbiology - strain-level considerations.